Route 92 Medical
PrivateLast Round
Series F
Extension
Apr 20, 2026
Total Funding Raised
$229.76M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Route 92 Medical is a medical technology company that develops advanced neurovascular solutions for the treatment of acute ischemic stroke.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Route 92 Medical Comparables
Compare Route 92 Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Q'Apel Medical | 91% | |
| Imperative Care | 88% | |
| Wallaby Medical | 85% |
Route 92 Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F Extension | Apr 20, 2026 | ||||
| Series F | Sep 23, 2024 | ||||
| Series F | Nov 16, 2023 | ||||
| Debt | Dec 14, 2021 | ||||
| Series E | Dec 14, 2021 | ||||
Series D | May 10, 2019 |
Key People
Founding team and executive leadership
Route 92 Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Runway Growth Capital | Debt |
| The Vertical Group | Series D, Series E, Series F Extension, Series C, Series A, Series F |
| InnovaHealth Partners | Series F Extension, Series F, Series E |
| U.S. Venture Partners | Series D, Series E, Series F Extension, Series C, Series A, Series F |
| Norwest Venture Partners | Series F Extension, Series F, Series E |
| Novo Holdings | Series F Extension, Series F |
| Sectoral | Series F Extension, Series F |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 70% MoM.
- Apr 24, 2026
Enrolling patients for the SUMMIT MAX randomized controlled trial under FDA IDE.
Recent news
Latest coverage and updates
- receives_financingOct 20, 2026
On Oct. 20th '26 in Utah, Route 92 Medical announces a $100M senior secured debt facility with Trinity Capital to strengthen its balance sheet and support continued product innovation and commercial growth.
Route 92 Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Route 92 Medical's valuation, stock price, and market status.
Is Route 92 Medical a public or private company?
Route 92 Medical is a private company.
What is the current stock price of Route 92 Medical?
Route 92 Medical is a private company, so its shares have no public market price. Caplight tracks Route 92 Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Route 92 Medical worth (valuation)?
Valuation information for Route 92 Medical is not publicly available.
Can I buy Route 92 Medical stock?
Route 92 Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Route 92 Medical's last funding round?
Route 92 Medical's most recent funding round was Series F Extension on April 20, 2026.
Who are the main investors in Route 92 Medical?
Key investors in Route 92 Medical include The Vertical Group, InnovaHealth Partners, U.S. Venture Partners, Norwest Venture Partners, Novo Holdings.
Will Route 92 Medical IPO soon?
No public IPO plans have been announced for Route 92 Medical.
How can I track Route 92 Medical secondary market activity?
Caplight tracks bids, offers, and trades in Route 92 Medical's shares on secondary markets.